SARS-CoV-2 NeutraLISA by EUROIMMUN
The SARS-CoV-2 NeutraLISA provides fast and economical determination of the inhibiting effect of anti-SARS-CoV-2 antibodies in patient samples, serving as a surrogate virus neutralisation test. The assay is based on competitive binding between neutralising antibodies in the samples and labelled ACE2 receptors to S1/RBD. The test supports evaluation of the immune response following SARS-CoV-2 infection or vaccination.